XML 20 R10.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Balance Sheet Components | 9 Months Ended
--- | ---
Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Balance Sheet Components | 4. Balance Sheet Components Cash Equivalents and Available-for-sale Securities Cash equivalents and available-for-sale securities consisted of the following (in thousands):
|  | September 30, 2016 |
|  | Amortized Cost |  |  | Gross Unrealized |  |  |  |
|  |  | Gains |  |  | Losses |  |  | Fair Value |
Money market funds |  | $ | 95,122 |  |  | $ | — |  |  | $ | — |  |  | $ | 95,122 |
Corporate bonds |  |  | 600 |  |  |  | — |  |  |  | — |  |  |  | 600 |
Commercial paper |  |  | 1,899 |  |  |  | — |  |  |  | — |  |  |  | 1,899 |
Total cash equivalents and available-for-sale securities |  | $ | 97,621 |  |  | $ | — |  |  | $ | — |  |  | $ | 97,621 |
Classified as: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash equivalents |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 95,122 |
Available-for-sale securities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,499 |
Total cash equivalents and available-for-sale securities |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 97,621 |
|  | December 31, 2015 |
|  | Amortized Cost |  |  | Gross Unrealized |  |  |  |
|  |  | Gains |  |  | Losses |  |  | Fair Value |
Money market funds |  | $ | 2,136 |  |  | $ | — |  |  | $ | — |  |  | $ | 2,136 |
Corporate bonds |  |  | 7,373 |  |  |  | — |  |  |  | (5 | ) |  |  | 7,368 |
Commercial paper |  |  | 500 |  |  |  | — |  |  |  | — |  |  |  | 500 |
Total cash equivalents and available-for-sale securities |  | $ | 10,009 |  |  | $ | — |  |  | $ | (5 | ) |  | $ | 10,004 |
Classified as: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash equivalents |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 2,136 |
Available-for-sale securities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7,868 |
Total cash equivalents and available-for-sale securities |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 10,004 |
All available-for-sale securities held as of September 30, 2016 and December 31, 2015 had contractual maturities of less than one year. There have been no material realized gains or losses on available-for-sale securities for the periods presented. Accrued Expenses and Other Payables Accrued expenses and other payables consisted of the following (in thousands):
|  | September 30, 2016 |  |  | December 31, 2015 |
Accrued clinical and research related expenses |  | $ | 1,630 |  |  | $ | 976 |
Accrued employee related expenses |  |  | 1,074 |  |  |  | 754 |
Other |  |  | 310 |  |  |  | 149 |
Total accrued expenses and other payables |  | $ | 3,014 |  |  | $ | 1,879 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References No definition available. + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration